Navigation Links
DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma
Date:3/31/2008

ed with enrollment from new sites that will open in the near future, should allow us to maintain our timelines for completion of accrual."

About AGENDA

AGENDA employs a biomarker to define those patients who derived maximum clinical benefit during a large randomized study of DTIC with or without Genasense, known as study GM301. These patients are characterized by low- normal levels of LDH (lactate dehydrogenase), a tumor-derived enzyme that is readily detected in blood. Analysis of the previous efficacy outcomes observed in 274 patients from GM301, which AGENDA is designed to confirm, yielded the following results:
Hazard

Endpoint Genasense/DTIC DTIC Ratio P

Overall response 20.8% 7.2% 0.002

Durable response 10.7% 2.4% 0.007

Progression-free

survival, median 3.6 mos. 1.6 mos. 0.58 <0.0001

Overall survival,

median 12.3 mos. 9.9 mos. 0.64 0.0009

A scientific article that describes efficacy and safety results from GM301 can be accessed at: http://www.jco.org/cgi/content/abstract/JCO.2006.06.0483v1.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium n
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DSMB Again Supports Continuation of the Phase III Clinical Trial of Medidur(TM) FA for the Treatment of DME
2. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
3. ACR Supports American Cancer Society Inclusion of CT Colonography (Virtual Colonoscopy) as Recommended Screening Tool for Colorectal Cancer in New Screening Guidelines
4. New Clinical Data Further Supports Chromium Picolinates Role in Enhancing Brain Activity in Older Adults
5. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
6. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
7. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
8. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
9. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
10. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
11. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter of 2013 will be approximately $53 ... million. "Our full-year revenue growth of 87% ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... VIENNA , April 23, 2010 AFFiRiS ... II clinical testing.,It may therefore be possible to confirm the ... start of this efficacy study comes only five,months after the ... in several disease areas and is currently developing a total ...
... LONDON , April 23, 2010 , , ... Managing uncertainty; A Migraine For Pharma Forecasters , , , ... has its up,s and down,s, with new markets,and products proving more complex and requiring sophisticated approaches to,forecast ... Dealing with uncertainties is no easy task. With ...
Cached Medicine Technology:AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 2AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 3AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 4MarketsandMarkets Partners With Eyeforpharma For The Pharma Forecasting Excellence Europe 2010 Summit 2MarketsandMarkets Partners With Eyeforpharma For The Pharma Forecasting Excellence Europe 2010 Summit 3
(Date:4/17/2014)... and alleviates muscle soreness after exercise, according to ... Illinois at Chicago. , The study, reported online ... of Physical Medicine and Rehabilitation , also showed ... had not exercised, suggesting that massage has benefits ... activity. , Improved circulation and relief of muscle ...
(Date:4/17/2014)... they suffer a cardiac arrest outside of a hospital ... to new research conducted at St. Michael,s Hospital. , ... arrest get adrenaline, which has been the drug recommended ... Lin, an emergency physician and trauma team leader at ... survival rates of patients who suffer a cardiac outside ...
(Date:4/16/2014)... the marvel of the embryo. It begins as a glob ... multiply to become the cells of our lungs, muscles, nerves ... Now, in a feat of reverse tissue engineering, Stanford University ... allows embryonic cells to proliferate and transform into all of ...
(Date:4/16/2014)... April 16, 2014 According to a new ... average-risk patients with one to two small polyps are ... cases. This may be an appropriate target for quality ... to quantify adherence to guidelines for timing of repeat ...
(Date:4/15/2014)... CHAMPAIGN, Ill. Scientists have solved a decades-old medical mystery ... to fight invasive fungal infections, which kill about 1.5 million people ... action of amphotericin, an antifungal drug that has been in use ... as toxic to human cells as it is to the microbes ...
Breaking Medicine News(10 mins):Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3
... Ind. - While biometric equipment is gaining popularity in ... to buildings, industries are finding that many users believe ... germs that could cause illness. , But a Purdue ... surfaces of devices that scan fingerprints or hand geometry ...
... In addition to the Spa, Six Signature Spa Suites Make Their ... Moon, the Caribbean,s Most Complete ... of Jamaica, the Honourable Bruce Golding, cut the ribbon to signal,the ... The Oct. 6 event marked the conclusion of a 15-month ...
... Department of,Veterans Affairs (VA) will augment its world-class ... grant received today from the Lilly Endowment,Inc. ... the Richard L. Roudebush VA Medical Center to ... from Iraq and Afghanistan and other,projects, including a ...
... news on research and advocacy reaches niche communities on ... RESTON, Va., Oct. 10 Voxant, the New ... 43,000 news videos,articles, and images dedicated to health news, ... Awareness month, and Voxant,has over 1,500 news assets that ...
... nutrition, physical activity and grieving programs, PITTSBURGH, ... than $580,000 in grants to four non-profit organizations,through ... will be used for,nutrition and physical activity programs ... program in Centre, Huntingdon and Mifflin counties. ...
... announced today that,their client, Critical Access HealthCare LLC ... critical access hospital in Borger,Texas. Ziegler Healthcare Consulting ... Under the terms of the Sept. 30 ... Golden Plains Community Hospital -- except for the ...
Cached Medicine News:Health News:Biometric sensors no dirtier than doorknobs, study finds 2Health News:Biometric sensors no dirtier than doorknobs, study finds 3Health News:Fern Tree, The Spa at Half Moon, Jamaica's Premier Spa, Opens With Ceremonial Ribbon Cutting 2Health News:Fern Tree, The Spa at Half Moon, Jamaica's Premier Spa, Opens With Ceremonial Ribbon Cutting 3Health News:Lilly Grant to VA Will Enhance Services for Returning Combat Veterans 2Health News:Voxant, the New Media Network, Distributes More Than 43,000 Health News Videos, Articles and Images 2Health News:Voxant, the New Media Network, Distributes More Than 43,000 Health News Videos, Articles and Images 3Health News:The Highmark Foundation Awards $580,000 in Highmark Healthy High 5 Grants to Four Non-Profit Organizations 2Health News:The Highmark Foundation Awards $580,000 in Highmark Healthy High 5 Grants to Four Non-Profit Organizations 3Health News:The Highmark Foundation Awards $580,000 in Highmark Healthy High 5 Grants to Four Non-Profit Organizations 4Health News:Ziegler Client, Critical Access HealthCare LLC, Acquires Texas Hospital 2Health News:Ziegler Client, Critical Access HealthCare LLC, Acquires Texas Hospital 3Health News:Ziegler Client, Critical Access HealthCare LLC, Acquires Texas Hospital 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: